A 52-year-old man with type 2 diabetes mellitus presents with a 3-month history of progressive polyuria, polydipsia, and weight loss despite being on metformin 1000 mg twice daily for the past 2 years. His current HbA1c is 9.2% (target <7%). Fasting blood glucose is 185 mg/dL and postprandial glucose is 245 mg/dL. He has no contraindications to any antidiabetic agent. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has inadequate glycaemic control on monotherapy (metformin) with HbA1c 9.2% and elevated fasting and postprandial glucose levels. The standard stepwise approach to type 2 diabetes management requires intensification when targets are not met. ## Rationale for Correct Answer **Key Point:** When HbA1c remains ≥7.5% on maximum-tolerated monotherapy, dual therapy is the next step before considering insulin or triple therapy [cite:KD Tripathi 8e Ch 55]. **High-Yield:** The 2023 ADA/EASD consensus and most Indian guidelines recommend adding a second agent (preferably a GLP-1 agonist, SGLT-2 inhibitor, or DPP-4 inhibitor for cardiovascular/renal benefit, or a sulfonylurea for rapid glucose lowering) rather than escalating monotherapy further. **Clinical Pearl:** This patient has already been on metformin 1000 mg twice daily (2000 mg/day), which is close to the maximum tolerated dose of 2550 mg/day. Further dose escalation carries diminishing returns and increased GI side effects; dual therapy is more effective. ## Why Dual Therapy Is Preferred - Targets different pathophysiological defects (metformin → insulin resistance; sulfonylurea/DPP-4 → β-cell dysfunction) - HbA1c reduction of 1.5–2% achievable with combination - Delays need for insulin - Safer metabolic profile than insulin monotherapy in this setting ## Agent Selection | Agent Class | Mechanism | Advantage | Caution | |---|---|---|---| | Sulfonylurea | Stimulates insulin secretion | Rapid HbA1c ↓ (1.5%) | Hypoglycaemia, weight gain | | DPP-4 inhibitor | Incretin potentiation | Neutral weight, safe | Modest effect (0.5–1%) | | GLP-1 agonist | Incretin mimetic | HbA1c ↓ 1–1.5%, weight loss, CV benefit | Cost, GI side effects | | SGLT-2 inhibitor | Urinary glucose excretion | CV/renal protection | Genital infections, DKA risk | **Tip:** In NEET PG, when a patient on monotherapy has HbA1c >7.5%, the examiner expects you to recognize that dual therapy is the next step—not maximum-dose monotherapy, not insulin yet.